Sen. Blumenthal Calls for Objective Review of New AI Products Before Release

Call for Pre-Release AI Review

Senator Richard Blumenthal (D-Conn.) stated that new artificial intelligence products should undergo an "objective review" before public release. His remarks were made during an interview on CNBC, where he discussed the increasing urgency for AI oversight.

Balancing Regulation and Competitiveness

Blumenthal, who has introduced bipartisan legislation concerning AI safety, acknowledged the need to balance regulatory measures with the imperative to maintain global competitiveness. He expressed concern that overly stringent regulation could hinder the U.S.'s AI development, while also noting that other nations, like China, are considering AI regulation due to potential threats.

He clarified that the goal is not a "regulatory state" but rather a form of scrutiny to prevent uncontrolled AI systems from operating autonomously.

Lessons from Past Technologies

The Senator drew a parallel between AI regulation and the Food and Drug Administration's (FDA) model for pharmaceutical oversight, suggesting that responsibility should be delegated to experts. He highlighted Congress's limitations in AI expertise.

Blumenthal also warned against repeating the delayed regulatory response seen with social media, where algorithms contribute to harmful content, and efforts to catch up are still ongoing.